ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Nowakowski, Grzegorz S., Chiappella, Annalisa, Gascoyne, Randy D., Scott, David W., Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E., Vitolo, Umberto
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2021
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078325/
https://ncbi.nlm.nih.gov/pubmed/33621109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01366
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items